Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

953 - Metformin in neoadjuvant systemic treatment in breast cancer patients with metabolic syndrome


10 Oct 2016


Poster display


Roman Liubota


Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365


R. Liubota1, A. Zotov1, R. Vereshchako1, V. Cheshuk1, N. Anikusko2, I. Liubota3

Author affiliations

  • 1 Department Of Oncology, O.O Bogomolets National Medical University Kiev, 01601 - Kiev/UA
  • 2 Surgery, Kyiv City Clinical Oncological Centre, 03115 - Kiev/UA
  • 3 Dispensary, Kyiv City Clinical Oncological Centre, 03115 - Kiev/UA


Abstract 953


The aim of this prospective randomized trial was investigate the influence of metformin on the effectiveness of neoadjuvant systemic anticancer therapy (NAST) breast cancer in patients with metabolic syndrome (MS).


The study included 54 patients (aged 46 to 77 years) who received neoadjuvant systemic treatment for stage II-III breast cancer, in the clinic of oncology National medical university named after O.O. Bogomolets based in Kiev municipal clinical oncological centre between 2010-2014. All patients was diagnosed MS according to the IDF criteria and were compared by 2 groups group 1 included 36 patients with MS and BC who did not take metformin during NAST, and group 2 - 18 metabolic syndrome patients with breast cancer taking metformin with NAST. Clinical and pathological response rates were compared between the two groups using the fourfold tables analysis method.


Clinical complete response (CR) was identified in 6%patients from group 1 and in 28% patients from group 2. Clinical benefit response of treatment (CR + PR) was achieved in 67% of patients treated with metformin compared to 25% patients from group 1. In 53% of patients who were not taking metformin was observed stabile disease (SD). The rate of pathological complete response (pCR) was 31% in the metformin group and 6% in the nonmetformin group.


Appointment metformin and neoadjuvant systemic anticancer therapy breast cancer patients with metabolic syndrome have a higher clinical and pathological CR rate and clinical benefit response of treatment than BC patient with MS not receiving metformin. This study demonstrated the potential of metformin as an antitumor agent in breast cancer patients with metabolic syndrome.

Clinical trial identification

Legal entity responsible for the study

Liubota Roman


NMU named after O.O. Bogomolets


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings